Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

Autor:	U. De Giorgi, Thomas Powles, J.M.G. Larkin, Gwenaelle Gravis, B. Escudier, Margitta Retz, Douglas O. Clary, John McCaffrey, Toni K. Choueiri, Robert J. Motzer, Michael Rink, Nizar M. Tannir, Claudia Caserta, Frederic Rolland, E. Esteban Gonzalez, Ignacio Duran, S. Cheporov, T. Csoszi, Michael Staehler, W.J. Berg
Rok vydání:	2016
Předmět:	Oncology Meteor (satellite) medicine.medical_specialty Everolimus Cabozantinib business.industry Hematology medicine.disease Surgery chemistry.chemical_compound chemistry Renal cell carcinoma Internal medicine medicine business Regional differences medicine.drug
Zdroj:	Annals of Oncology. 27:vi285
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8ae272bd62a6e93ae83d86dc8eed5ef8 https://doi.org/10.1093/annonc/mdw373.45 Zobrazit plný text záznamu